Since P/LP variants in RAD50 and MUTYH genes do not have sufficient evidence of its association with an increased risk of breast and/or ovarian cancer (Fan et al., 2018; Tung et al., 2016), no risk‐reducing measures should be offered to these carriers and risk assessment must be based on family history and other personal risk factors (NCCN Guidelines Version 1., 2023). This evidence concerns the gene RAD50 and ovarian carcinoma.